Drug Profile
Autologous stem cell therapy - DaVinci Biosciences
Alternative Names: DVM™Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator DaVinci Biosciences
- Class Cell therapies; Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Spinal cord injuries
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Spinal-cord-injuries in Ecuador (Parenteral)
- 21 Oct 2009 Interim efficacy and adverse events data from a clinical trial in Spinal cord injuries presented at the 39th Annual Meeting of the Society for Neuroscience (SfN- 2009),
- 12 Mar 2009 Clinical trials in Spinal cord injuries in Ecuador (Parenteral)